Literature DB >> 15933586

Optical coherence tomography in unilateral resolved central serous chorioretinopathy.

Chiara M Eandi1, Juliet E Chung, Felice Cardillo-Piccolino, Richard F Spaide.   

Abstract

PURPOSE: To evaluate the correlation between optical coherence tomographic evaluations of foveal thickness and anatomical changes within the fovea and visual acuity in patients who have unilateral resolved central serous chorioretinopathy.
METHODS: A retrospective review of cases of unilateral resolved central serous chorioretinopathy imaged with high-resolution optical coherence tomography was performed. The foveal thickness of the involved eye was normalized by dividing its thickness by that of the uninvolved fellow eye. The best-corrected visual acuity of the involved eye was normalized as well. The normalized foveal thickness was compared with the normalized visual acuity. The anatomical findings of the fovea were compared with the visual acuity.
RESULTS: Twenty patients were evaluated (11 men and 9 women; age range, 31-66 years [mean, 46.8 years]). The mean foveal thickness was 135.8 mum in the involved eyes and 184.4 mum in the uninvolved eyes (P < 0.001). There was a correlation between the normalized foveal thickness and the normalized visual acuity (Spearman rho, 0.67; P = 0.001). The external limiting membrane was visible in 7 (35%) of the involved eyes compared with 19 uninvolved eyes (95%) (P < 0.001). In the involved eyes, those with a visible external limiting membrane had better visual acuity than did those that did not (P = 0.001). It was possible to visualize the boundary between the photoreceptor cell bodies and the outer segments in 8 (40%) of the involved eyes and in the 17 uninvolved eyes (85%) (P < 0.001). In the involved eyes, those with a visible boundary between the photoreceptor bodies and the outer segments had a better visual acuity than did those that did not (P = 0.019).
CONCLUSIONS: Patients with unilateral resolved central serous chorioretinopathy had a decrease in the central foveal thickness in the involved eyes, and there was a statistically significant correlation between the foveal thickness and the visual acuity, even in eyes with relatively good visual acuity. The inability to observe a discrete signal corresponding to the external limiting membrane layer was more common in involved eyes and was significantly associated with decreased visual acuity. This same relationship was seen with the ability to visualize the boundary between the photoreceptor bodies and the outer segments; this boundary was less commonly observed in involved eyes and was associated with decreased visual acuity. Resolved central serous chorioretinopathy causes a number of morphologic changes in the fovea that are associated with visual acuity.

Entities:  

Mesh:

Year:  2005        PMID: 15933586     DOI: 10.1097/00006982-200506000-00004

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  24 in total

1.  The association between percent disruption of the photoreceptor inner segment-outer segment junction and visual acuity in diabetic macular edema.

Authors:  Anjali S Maheshwary; Stephen F Oster; Ritchie M S Yuson; Lingyun Cheng; Francesca Mojana; William R Freeman
Journal:  Am J Ophthalmol       Date:  2010-05-10       Impact factor: 5.258

2.  Suprachoroidal electrotransfer: a nonviral gene delivery method to transfect the choroid and the retina without detaching the retina.

Authors:  Elodie Touchard; Marianne Berdugo; Pascal Bigey; Mohamed El Sanharawi; Michèle Savoldelli; Marie-Christine Naud; Jean-Claude Jeanny; Francine Behar-Cohen
Journal:  Mol Ther       Date:  2012-01-17       Impact factor: 11.454

3.  External limiting membrane as a predictor of visual improvement in diabetic macular edema after pars plana vitrectomy.

Authors:  Jay Kumar Chhablani; Jae Suk Kim; Lingyun Cheng; Igor Kozak; William Freeman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-02-23       Impact factor: 3.117

4.  Spectral domain ocular coherence tomography findings pre- and post vitrectomy with fibrovascular membrane delamination for proliferative diabetic retinopathy.

Authors:  I Dooley; H Laviers; E Papavasileiou; C Mckechnie; H Zambarakji
Journal:  Eye (Lond)       Date:  2015-09-25       Impact factor: 3.775

5.  Association between integrity of foveal photoreceptor layer and visual acuity in branch retinal vein occlusion.

Authors:  Masafumi Ota; Akitaka Tsujikawa; Tomoaki Murakami; Mihori Kita; Kazuaki Miyamoto; Atsushi Sakamoto; Noritatsu Yamaike; Nagahisa Yoshimura
Journal:  Br J Ophthalmol       Date:  2007-05-15       Impact factor: 4.638

6.  Association between foveal photoreceptor status and visual acuity after resolution of diabetic macular edema by pars plana vitrectomy.

Authors:  Atsushi Sakamoto; Kazuaki Nishijima; Mihori Kita; Hideyasu Oh; Akitaka Tsujikawa; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-09       Impact factor: 3.117

7.  [Three-dimensional imaging in central serous chorioretinopathy].

Authors:  G Stock; C Ahlers; R Sayegh; M Ritter; S Kolar; I Golbaz; U Schmidt-Erfurth
Journal:  Ophthalmologe       Date:  2008-12       Impact factor: 1.059

8.  Restoration of outer segments of foveal photoreceptors after resolution of central serous chorioretinopathy.

Authors:  Yumiko Ojima; Akitaka Tsujikawa; Kenji Yamashiro; Sotaro Ooto; Hiroshi Tamura; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2010-02-12       Impact factor: 2.447

Review 9.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

10.  The IS/OS junction layer in the natural history of type 2 idiopathic macular telangiectasia.

Authors:  Ferenc B Sallo; Tunde Peto; Catherine Egan; Ute E K Wolf-Schnurrbusch; Traci E Clemons; Mark C Gillies; Daniel Pauleikhoff; Gary S Rubin; Emily Y Chew; Alan C Bird
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-11-29       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.